Contents

Volume 80 Issue 12 | ARD December 2021

Editorial

1503 Towards clinical significance of the MUC5B promoter variant and risk of rheumatoid arthritis-associated interstitial lung disease
J A Sparks

Viewpoint

1505 Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology
S J W Stock-Warrall, K Cresswell, J Bolger, B Dillon, K L Hynie, N Geifman, Members of the CLUSTER consortium

Review

1511 Axial spondyloarthritis
V Navarro-Campión, A Sepúlveda, B El-Zorkany, D van der Heijde

Rheumatoid arthritis

1522 Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naïve patients with rheumatoid arthritis
A J Ocon, G Reed, D A Pappas, J R Curtis, J M Kremer

1530 Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers
A Palomäki, FinnGen Rheumatology Clinical Expert Group, A Palotie, J Koskela, K K Ekholm, M Pirinen, FinnGen, S Ripatti, T Laitinen, N Mars

1537 B cell depletion impairs vaccination-induced CD8+ T cell responses in a type I interferon-dependent manner
T Graulmann, K Borst, H Mantlanda, L Vaas, M Bruhn, L Graulmann, M Koster, M Verboom, M Hallensleben, C A Guzmán, G Sutter, R E Schmidt, T Witte, U Kalinke

Psoriatic arthritis

1553 Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia

1559 Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid
N Yager, S Cole, A Lleda Lara, A Marof, P Penkava, J C Knight, P Bowness, H Al-Mosawi

Systemic lupus erythematosus

1568 Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity
D Jesus, M Larosa, C Henriques, A Matos, M Zen, P Tomé, V Alves, N Costa, V Le Guem, L Laccarino, N Coste-Chatumeau, A Doria, L S Insé

1575 Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese

Inflammatory arthritis

1545 Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility)

MORE CONTENTS ►

Disclaimer: The Editor of ARD has been granted editorial freedom and ARD is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. ARD is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy and completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by ARD does not imply endorsement. Neither BMJ nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from ARD (except for liability which cannot be legally excluded).

Copyright: © 2021 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved. No part of this publication may be reproduced in any form without permission. ARD is published by BMJ Publishing Group Ltd on behalf of the World Association of Medical Editors and the European League Against Rheumatism. All rights reserved. Printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPF 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Artwork and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Annals of the Rheumatic Diseases, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

This article has been chosen by the Editor to be of special interest or importance and is freely available online. This article has been made freely available online under the BMJ Journals open access scheme. See http://authors.bmj.com/open-access/electronicRights/COPE | http://publicationethics.org/
**Systemic sclerosis**

1584 Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis  
K E N Clark, C Campochiaro, E Comor, A Taylor, K Nevin, N Galwey, M A Morse, J Singh, Y V Teo, V H Ong, E Derrett-Smith, N Wisnacki, S M Flint, C P Denton

1594 TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis  

**Crystal arthritis**

1604 Mechanosensitive TRPV4 is required for crystal-induced inflammation  
Z Lan, L Chen, J Feng, Z Xie, Z Liu, F Wang, P Liu, X Yue, L Du, Y Zhao, P Yang, J Liu, Z Zhu, X Hu, L Cao, P Lu, R Sah, K Laveine, B Kim, H Hu

**Osteoarthritis**

1615 14-3-3 epsilon is an intracellular component of TNFR2 receptor complex and its activation protects against osteoarthritis  
W Fu, A Heriinghouse, Y Chen, W Hu, X Ding, M Chen, Y Ding, Mundra, W Song, R Liu, Y-S Yi, M Amor, J Samuels, E Strauss, P Leucht, R Schwarzlopp, C Liu

**Letters**

1628 Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy  
M R A Shipa, R Amarnani, S-A Yeoh, M D Malladinn, M R Ehrenstein

1629 Nail involvement in psoriatic arthritis patients is an independent risk factor for carotid plaque  

1631 Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study  
Y Liu, Z Ji, W Yu, S Wu, H Chen, L Ma, Z Ding, L Jiang

1633 Immunotheories and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System  
M Pistor, A G F Hoepner, Y Lin, S Jung, C L Bassetti, A Chau, A Salmen, R Hoepner

1635 Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis  
S Bugiani, L De Stefano, S Baldazzi, M I Greco, T Luvato, I Cassaniti, I Bogliolo, I Mazzucchelli, B D’Onofrio, M di Lernia, E Mauric, D Lilleri, F Baldanti, A Manzo, C Montecucco

1638 Unexpected impact of COVID-19 lockdown on spinal mobility and health perception in spondylarthritis  
S De Misis, A-S De Comer, I Deroo, T Reuson, F E Van den Bosch, P Carrou, D Elewa

**Electronic pages**

e188 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view  
M Infantino, M Manfredi, N Bizzarri, On behalf of the Study Group on Autoimmune Diseases of the Italian Society of Clinical Pathology and Laboratory Medicine

e189 Response to: ‘European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view’ by Infantino et al  
M Aringer, K H Costenbader, T Dorner, S R Johnson

e190 New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion  
K Sacre, I Delaval, A Dossier, J-F Alexandre, M Berleur, M-P Chauvet, G Ducrocq, T Coulon, D van Gysel, D Rouzaud, T Papo

e191 Response to: ‘New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion’ by Sacre et al  
M Aringer, K Costenbader, T Dorner, S R Johnson
e192 Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus
B Wang, S Chen, Q Zheng, Z Gao, R Chen, J Xuan, Y Liu, C Shi

e193 Response to: ‘Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus’ by Wang et al
M Aringer, K Costenbader, T Dörner, S R Johnson

e194 NCF1-339 polymorphism and systemic lupus erythematosus
B Joob, V Wiwanitkit

e195 Response to: ‘NCF1-339 polymorphism and systemic lupus erythematosus’ by Joob and Wiwanitkit
C P Linge, A Bengtsson

e196 Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors
A Meyer, P S Witschel, K Kotschenreuther, J Schiller, J von Tresckow, T H Haak, D M Kofler

e197 Response to: ‘Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors’ by Meyer et al
M Rosenzweig, R Lorenzon, D Klattman

e198 Correspondence to ‘Slope sign’: a feature of large vessel vasculitis?
M Milchert, M Brezsko, A Bull Haaversen, A P Diamantopoulos

e199 Response to: ‘Correspondence to ‘Slope sign’: a feature of large vessel vasculitis?’ by Milchert et al
A Sebastian, A Kayani, B Dasgupta

e200 Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares
A M Didierlaurent, C Dessart, A L Cunningham

e201 Response to: ‘Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares’ by Didierlaurent et al
C Yokose, H Choi

e202 Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care
K Parperis

e203 Response to: ‘Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care’ by Parperis et al
E Reddy, C D Mallen, on behalf of the CONTACT trial authors

e204 Association between osteoporosis and statins therapy: the story continues
A M Burden, S Weiler

e205 Response to: ‘Association between osteoporosis and statins therapy: the story continues’ by Burden and Weiler
M Leuner, C Matzfeld, I Bellach, C Deischinger, J Harreiter, S Thurner, P Klimek, A Kautzky-Willer